Company Overview of Allergan USA, Inc.
Allergan USA, Inc. offers pharmaceutical products and medicines. It acquires, develops, and markets pharmaceutical products for patient wellness within the genito-urinary and women’s healthcare markets. The company offers SANCTURA, a treatment for over-active bladder; PRO-QUIN, a treatment for urinary tract infections; and ESTRASORB to treat various symptoms of menopause, as well as PROSED line of urinary analgesic-antiseptic products. Allergan USA, Inc. was formerly known as Esprit Pharma, Inc. The company was incorporated in 2004 and is based in Irvine, California. As of October 16, 2007, Allergan USA, Inc. operates as a subsidiary of Allergan Inc.
2525 Dupont Drive
Irvine, CA 92612
Founded in 2004
Key Executives for Allergan USA, Inc.
Chairman of the Board and Chief Executive Officer
President and Chief Operating Officer
Vice President and Chief Financial Officer
Compensation as of Fiscal Year 2014.
Allergan USA, Inc. Key Developments
Allergan USA, Inc. Receives $37.24 Million Federal Contract
Mar 25 14
Allergan USA Inc. was awarded a federal contract valued at up to $37,242,251 by the Defense Logistics Agency Troop Support, Philadelphia, for various pharmaceutical surge, re-supply and sustainment products for the U.S. Army, U.S. Navy, U.S. Air Force, U.S. Marine Corp. and federal civilian agencies.
Consumer's Class Action Alleging Allergan USA Inc., Allergan Inc. and Allergan Sales L.L.C. Overfills Dispensers Dismissed
Feb 21 14
The U.S. District Court for the Eastern District of Missouri held the manufacturers of Restasis eye drops were entitled to the dismissal of a consumer's class action alleging the manufacturers overcharged for the eye drops. The consumer failed to state a claim under Missouri law. Alternatively, the consumer's claims were preempted by federal law. Restasis was a prescription ophthalmic medication manufactured and sold by Allergan USA Inc., Allergan Inc. and Allergan Sales L.L.C. in vials. Each vial of Restasis contained approximately 14 drops of medicine, while the recommended dosage for Restasis was one drop twice a day. Thompson alleged violation of the Missouri Merchandising Practices Act (MMPA). She also alleged the defendants were unjustly enriched by their practice of overfilling Restasis dispensers and received money from "deceptive and unfair practices." The defendants moved to dismiss for failure to state a claim upon which relief could be granted and, alternatively, on federal preemption grounds. The district court granted the defendants' motion. Thompson's allegation that including smaller quantities of medication in the Restasis vials would make it less expensive to consumers was without sufficient logical or factual foundation. She therefore failed to meet the ascertainable loss requirement for stating a claim under the MMPA. Similarly, her claims for unjust enrichment and money had and received also failed. The district court also found that reducing the amount of medicine in each Restasis vial was a major change requiring prior Food and Drug Administration approval.
Spectrum Pharmaceuticals, Inc. Announces Second Amendment to the License, Development, Supply and Distribution Agreement with Allergan
Jan 31 13
On January 29, 2013, Spectrum Pharmaceuticals, Inc. entered into a Second Amendment to the License, Development, Supply and Distribution Agreement, dated October 28, 2008, as amended June 13, 2011, by and among the company, Allergan Sales LLC, Allergan USA, Inc. and Allergan Inc. Under the Amendment, among other things, the parties agreed to restructure their collaboration with respect to Apaziquone, with Spectrum buying back the rights it originally licensed to Allergan in the U.S., Europe and other territories in exchange for a tiered single digit royalty not to exceed mid single digits on certain products containing Apaziquone, and Allergan being relieved of its obligations for development, commercialization and other activities.
Similar Private Companies By Industry
Recent Private Companies Transactions